{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable because insufficient number of participants have events (progressed or relapsed).","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"11.33"},{"comment":"Not estimable because insufficient number of participants have events (progressed or relapsed).","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Not estimable because insufficient number of participants have events (progressed or relapsed).","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG003","lowerLimit":"2.00","upperLimit":"82.07","value":"82.07"},{"comment":"Not estimable because insufficient number of participants have events (progressed or relapsed).","groupId":"OG004","lowerLimit":"0.92","upperLimit":"NA","value":"NA"},{"comment":"Not estimable because insufficient number of participants have events (progressed or relapsed).","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"33"}],"units":"Participants"}],"description":"PFS was measured from the start of moxetumomab pasudotox treatment until the first documentation of disease progression/relapse or death, whichever occurred first. PFS was summarized using Kaplan-Meier estimates (median time, 95% CI for median time).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received IV 5 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued until complete response (CR), progressive disease (PD), initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG000","title":"5 mcg/kg"},{"description":"Participants received IV 10 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG001","title":"10 mcg/kg"},{"description":"Participants received IV 20 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG002","title":"20 mcg/kg"},{"description":"Participants received IV 30 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG003","title":"30 mcg/kg"},{"description":"Participants received IV 40 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG004","title":"40 mcg/kg"},{"description":"Participants received IV 50 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG005","title":"50 mcg/kg"}],"paramType":"MEDIAN","populationDescription":"Safety population included all participants who received any treatment of moxetumomab pasudotox.","reportingStatus":"POSTED","timeFrame":"From Baseline (predose of Cycle 1 Day 1) through end of study (until CR, PD, initiation of alternative therapy, unacceptable toxicity, development of neutralizing antibodies, or other study discontinuation reasons) (approximately 8 years)","title":"Progression-free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"months"}